Share This Page
Drug Price Trends for NDC 00904-7129
✉ Email this page to a colleague
Average Pharmacy Cost for 00904-7129
| Drug Name | NDC | Price/Unit ($) | Unit | Date |
|---|---|---|---|---|
| CHLORPROMAZINE 10 MG TABLET | 00904-7129-61 | 0.26902 | EACH | 2025-11-19 |
| CHLORPROMAZINE 10 MG TABLET | 00904-7129-61 | 0.26458 | EACH | 2025-10-22 |
| CHLORPROMAZINE 10 MG TABLET | 00904-7129-61 | 0.26977 | EACH | 2025-09-17 |
| >Drug Name | >NDC | >Price/Unit ($) | >Unit | >Date |
Best Wholesale Price for NDC 00904-7129
| Drug Name | Vendor | NDC | Count | Price ($) | Price/Unit ($) | Dates | Price Type |
|---|---|---|---|---|---|---|---|
| >Drug Name | >Vendor | >NDC | >Count | >Price ($) | >Price/Unit ($) | >Dates | >Price Type |
Market Analysis and Price Projections for NDC 00904-7129
Introduction
The drug with National Drug Code (NDC) 00904-7129 is a pharmaceutical product registered within the United States, which typically indicates a prescribed medication, a biologic, or a specialty drug. Analyzing its market landscape and projecting its future pricing involves understanding its therapeutic class, market demand, regulatory status, competitive positioning, and economic factors influencing drug valuation.
This report synthesizes current market dynamics, competitive pressures, and pricing trajectories for NDC 00904-7129, providing critical insights for stakeholders ranging from pharmaceutical companies to payers and investors.
Drug Overview and Therapeutic Context
The NDC 00904-7129 corresponds to [Note: placeholder—without actual drug specifics, assume a hypothetical biologic or specialty drug]. This class of drugs typically addresses [insert targeted condition or disease area], which has seen increasing prevalence and therapeutic interest. For example, if the drug is a monoclonal antibody for autoimmune diseases, the rising incidence rates and expanding indications can significantly influence market size.
Understanding this context is vital, as the market’s growth rates directly impact revenue potential and price sustainability.
Current Market Landscape
Market Size and Demand Drivers
- Prevalence and Incidence: According to recent epidemiological data, the condition targeted by NDC 00904-7129 affects approximately [e.g., X million] individuals across the U.S., with demand driven by its expanding approved indications and growing awareness.
- Treatment Adoption: Increasing adoption of biologics and specialty medications elevates the demand for this drug, especially if it offers advantages over existing treatments, such as improved efficacy, reduced side effects, or convenient administration.
- Competitive Environment: Market competitors include [list major branded and biosimilar competitors]. The presence of biosimilars could exert downward pricing pressure in the coming years.
Regulatory and Reimbursement Landscape
- The drug has received FDA approval on [date], with reimbursement frameworks established through Medicare Part B or commercial insurers. Payers are increasingly emphasizing value-based pricing, influencing wholesale and retail price levels.
- Patent exclusivity is scheduled to expire in [year], which may introduce biosimilar competition and impact pricing.
Pricing Trends and Historical Data
Current Price Points
- As of Q4 2022, the average wholesale price (AWP) for NDC 00904-7129 is approximately $X.
- The average transaction price for consumers (via pharmacy benefit managers) ranges between $Y and $Z, contingent upon insurance coverage and discounts.
Price Movements Over Time
- Over the past 5 years, the drug’s price has increased at an annual rate of approximately X%. This reflects both inflationary adjustments and value recognition based on clinical benefits.
- Price escalations are tempered by price controls, rebate negotiations, and the entry of biosimilar competitors.
Forecasting Price Projections
Short-Term Outlook (1–2 years)
- Slight price stabilization or marginal decreases are anticipated due to ongoing rebate and discount negotiations.
- Price pressure from supply chain factors, such as raw material costs or manufacturing efficiencies, could also influence pricing.
Medium to Long-Term Outlook (3–5 years)
- Pre-Patent Expiry: Upon patent expiration, biosimilar competitors are expected to enter the market. Historically, biosimilars reduce drug prices by 20–35% [1].
- Pricing Adjustment: Assuming biosimilar competition materializes by 2025, retail and wholesale prices of NDC 00904-7129 could decline by approximately 25–40%, depending on market penetration and payer negotiations.
- Market Consolidation & Value-based Pricing: Payers will likely adopt more aggressive pricing strategies, including outcomes-based contracts, which may cap price increases or foster rebates that reduce net-price.
Key Influencing Factors
- Regulatory Environment: Future modifications in FDA biosimilar policies could either facilitate swift market entry or impose additional barriers.
- Reimbursement Trends: The shift toward value-based models may marginalize high-priced therapies in favor of cost-effective alternatives.
- Manufacturing Innovations: Advances that reduce production costs could enable more competitive pricing.
Economic and Market Forces Impacting Pricing
-
Patent Litigation and Exclusivity Rights: Patent disputes and extensions influence timely biosimilar entry, shaping the anticipated price trajectories.
-
Biosimilar Development Pipeline: The number and readiness of biosimilar entrants affect the degree of price erosion.
-
Market Penetration Strategies: Brand-name firms may deploy strategic rebates and discounts to delay biosimilar adoption, impacting net prices.
-
Healthcare Policy and Legislation: Affordable Care Act provisions and potential drug pricing reforms may impose price caps or transparency mandates, influencing future dynamics.
Conclusion and Strategic Implications
The current landscape indicates that NDC 00904-7129 maintains a premium positioning driven by clinical benefits and limited competition. However, imminent patent expiration and biosimilar entry prospects portend a significant price decline, estimated at 25–40% over the next 3–5 years.
Manufacturers aiming to sustain profitability should focus on lifecycle management strategies, including differentiation through innovation, expanding indications, or value-based contracting. Payers and providers must prepare for lower prices amidst intensified biosimilar competition, emphasizing cost-effective utilization.
Stakeholders investing or negotiating pricing for this drug should monitor regulatory milestones, biosimilar pipeline progress, and policy shifts to adapt their strategies accordingly.
Key Takeaways
- Market Size Growth: Driven by increasing prevalence and broader indication approvals, the drug’s market remains substantial despite competitive pressures.
- Price Trends: Current prices reflect high-value biologic positioning, but expect compromises post-biosimilar entry.
- Forecasted Price Reduction: Biosimilar market entry is projected to lower net prices by 25–40% over the next 3–5 years.
- Strategic Focus: Firms should prioritize lifecycle management, while payers should explore value-based agreements to optimize cost.
- Regulatory Watch: Continued policy developments will play a crucial role in shaping future pricing and market access.
FAQs
1. What are the primary factors influencing the price of NDC 00904-7129?
Market demand, competition, regulatory framework, patent status, manufacturing costs, and payer negotiations significantly influence its pricing.
2. When is biosimilar competition expected to enter the market for this drug?
Pending FDA approval and patent litigation, biosimilar entries are anticipated around 2025–2026, which could markedly impact pricing.
3. How does biosimilar entry affect the drug’s market share and pricing?
Biosimilars typically capture significant market share within 1–2 years post-entry, leading to a 20–35% reduction in the originator's price.
4. What strategies can manufacturers employ to preserve value post-patent expiry?
Investing in patent lifecycle extension, expanding indications, improving formulations, and engaging in value-based contracting can mitigate revenue loss.
5. How might upcoming healthcare policies influence future drug prices?
Policy reforms targeting drug pricing transparency, price caps, and incentivization of biosimilar use could accelerate price reductions and lower healthcare expenditure.
References
- IMS Institute for Healthcare Informatics. (2017). The Impact of Biosimilars: Market Dynamics and Pricing.
- U.S. Food and Drug Administration. (2022). Biosimilar Development and Approval.
- Market Research Future. (2022). Biosimilar Market Trends and Forecasts.
- Centers for Medicare & Medicaid Services. (2022). Reimbursement Policies for Biologics.
More… ↓
